April 2026
M	T	W	T	F	S	S
	1	2	3	4	5
6	7	8	9	10	11	12
13	14	15	16	17	18	19
20	21	22	23	24	25	26
27	28	29	30

Jack Shuang Hou: CorTec Wins FDA TAP Entry for Brain Interchange

Jack Shuang Hou/CorDx/LinkedIn

Apr 24, 2026, 08:20

Jack Shuang Hou: CorTec Wins FDA TAP Entry for Brain Interchange

Jack Shuang Hou, Scientific Director at Jtests and CorDx, shared on LinkedIn:

”CorTec Wins FDA TAP Entry for Brain Interchange – Frank Desiere Highlights Third Stroke Rehab Implant as BCI Program Gains Regulatory Momentum

A meaningful neurotech milestone: CorTec has now secured both FDA Breakthrough Device Designation and acceptance into the FDA Total Product Life Cycle Advisory Program (TAP) for Brain Interchange in stroke motor rehabilitation, while advancing its NIH-funded clinical study with a third patient implanted at Harborview Medical Center.

Key leaders

Frank Desiere – PhD MBA — Chief Executive Officer, CorTec
Jeff Ojemann, MD — Vice Chair and Professor of Neurological Surgery, University of Washington – School of Medicine
Martin Schuettler — Chief Technology Officer and Co-Founder, CorTec
Mara Assis – Head of Regulatory Affairs and Quality Management, CorTec

FDA validation goes beyond breakthrough status

Brain Interchange accepted into FDA TAP, a limited program for priority breakthrough technologies
TAP adds structured FDA support on study design, regulatory strategy, and early payer engagement including CMS
This follows CorTec’s recent Breakthrough Device Designation for stroke rehabilitation.

Strategic impact:
This is not just a regulatory badge – it strengthens the path from clinical evidence – approval – reimbursement.

Clinical execution is advancing in parallel

Third patient implanted at Harborview Medical Center in Seattle
Trial is NIH-funded, FDA-authorized, and conducted by researchers from University of Washington and UCLA
First participant has now shown nine months of stable wireless sensing and cortical stimulation performance.

Signal:
CorTec is building both regulatory momentum and real human durability data at the same time.

A European neurotech platform gaining global relevance

Brain Interchange is a fully implantable, wireless, bidirectional closed-loop BCI
CorTec says it is the only European company with such a platform in FDA-authorized U.S. clinical evaluation
The platform is also being explored in epilepsy, depression, and communication restoration.

My takeaway

This is a strong example of how next-generation neurotech wins:

differentiated platform
durable implant performance
smart regulatory sequencing
early reimbursement thinking

Bottom line
CorTec is moving Brain Interchange from promising BCI concept toward a real therapeutic platform for stroke recovery, and FDA TAP entry materially increases the credibility of that path.”

Jack Shuang Hou: CorTec Wins FDA TAP Entry for Brain Interchange